Drugmaker Regeneron Pharmaceuticals Inc beat analysts' estimates for third-quarter profit on Tuesday, boosted by higher sales of its eczema drug, Dupixent, and blockbuster eye drug Eylea.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,